There currently exist a great number of different mouse lines in which the activity of a particular gene of interest has been inactivated or enhanced. However, it is also possible to insert specific mutations in a gene so that the pharmacological sensitivity of the gene product is altered. An example of such an approach shows how the abolition of the sensitivity of an L-type Ca 2+ channel isoform to dihydropyridines allows the investigation of the physiological role of these channels in different tissues .
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The LTCC family L-type Ca 2+ channels (LTCCs) are formed by different pore-forming α1 subunit isoforms named Ca v 1.1, Ca v 1.2, Ca v 1.3, and Ca v 1.4 associated to auxiliary subunits (α2-δ, β, and γ) (1). The common pharmacological hallmark of all native and recombinant LTCCs is their sensitivity to dihydropyridines (DHPs). However, the small differences among the LTCC α1 isoforms in their affinity for DHPs (agonists and antagonists) have limited the study of the functional role of these channels in various tissues, including the cardiovascular system, the brain, and the endocrine glands. In this issue of the JCI, Sinnegger-Brauns and coworkers report that they have developed a new mouse model resulting from a knock-in mutation of the Ca V 1.2 voltage-dependent LTCC subunit which abolishes the sensitivity of the channel to DHP (referred to herein as the Ca V 1.2DHP -/-mouse) (see Figure 1) 
Ca v 1.2 versus Ca v 1.3 in insulin secretion
Using the Ca V 1.2DHP -/-mice that exhibit a normal phenotype in spite of their DHPinsensitive Ca v 1.2 channels, the authors have been able to differentiate, both in vivo and in vitro, the roles of the Ca v 1.2 and Ca v 1.3 channels in insulin secretion, cardiac performance, and mood behavior (2) . In particular, the finding that insulin secretion in these mice was completely insensitive to DHP agonists and antagonists provides strong evidence in the long-standing debate about the insulin secretagogue role of the Ca v 1.2 and Ca v 1.3 channels. Opposite conclusions about the importance of the Ca v 1.3 LTCC in this secretion process have been drawn by two previous studies using different mouse strains lacking the Ca v 1.3 LTCC (7, 8) and a β-cell-specific knockout of the Ca v 1.2 LTCC (9). The complete resistance of the insulin secretory process to DHPs in the Ca V 1.2DHP -/-mice strongly supports the minor role of Ca v 1.3 in this process.
LTCC isoforms in mood behavior
Another important aspect of the study concerns the role of the Ca v 1.3 LTCC in integrated neuronal functions. While the expression of the Ca v 1.2 LTCC isoform accounts for about 80% of the overall DHP-binding sites in the brain, the remaining 20% of binding can be attributed to Ca v 1.3 LTCCs, and little was known about the function of these channels. Indeed, DHP agonists such as BayK8644 cannot be used in vivo because of potent neurotoxic effects mediated by Ca v 1. Relevance of the Ca V 1.2DHP -/-mouse in the study of heart physiology The Ca V 1.2DHP -/-mouse model can also help to reveal the functional role of LTCCs in the physiology of the heart. It is widely accepted that the Ca v 1.2 subunit constitutes the most abundant LTCC subunit in the heart, where it plays an important role in excitation-contraction coupling in the working myocardium. In addition, a growing body of evidence indicates that the functional roles of Ca v 1.2 and Ca v 1.3 channels are distinct in the heart, with Ca v 1.3 channels playing a major role in pacemaker activity. Indeed, the fact that mice in which the gene encoding the Ca v 1.3 subunit has been inactivated show prominent dysfunctions in pacemaker activity in
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LTCCs are multimeric complexes of subunits formed by an α1 pore-forming protein associated to three auxiliary subunits (α2-δ, β, and γ). vivo and in vitro demonstrates that Ca v 1.3 channels constitute the major component of the L-type current in pacemaker cells (8, 11, 12) . Experimental results presented by Sinnegger-Brauns and coworkers clearly support this view (2) . More generally, the use of engineered mice such as Ca V 1.2DHP -/-mice will be of particular interest to further assess the contribution of the different ionic currents underlying diastolic depolarization in sinoatrial pacemaker cells. Automaticity in cardiac pacemaker cells is due to the slow diastolic depolarization phase, which drives the membrane voltage from the end of the action potential to the threshold of the following action potential. Both native and recombinant Ca v 1.3 channels exhibit more negative threshold for activation and slower inactivation kinetics than Ca v 1.2 channels. In other words, the low threshold of Ca v 1.3 current is consistent with a major role during diastolic depolarization (12) , while a sustained calcium influx is required for the contractility of heart cells.
In conclusion, the originality of this model offers stimulating prospects for dissecting the physiological roles of calcium channels in various tissues (2) . This genetic "reverse" pharmacology in vivo is likely to be applied in the future to other channels and receptor families sharing a similar pharmacology.
